Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.

Oguh-Olayinka L, Agarwal V, Ranatunge D, Campbell A, Laufer S, Cawkwell L, Lind MJ.

Pathol Oncol Res. 2019 Apr 2. doi: 10.1007/s12253-019-00652-x. [Epub ahead of print]

PMID:
30941737
2.

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome.

Till KJ, Allen JC, Talab F, Lin K, Allsup D, Cawkwell L, Bentley A, Ringshausen I, Duckworth AD, Pettitt AR, Kalakonda N, Slupsky JR.

Sci Rep. 2017 Dec 1;7(1):16784. doi: 10.1038/s41598-017-17021-w.

3.

Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.

Garimella V, Hussain T, Agarwal V, Radhakrishna S, Fox JN, Kneeshaw PJ, Long ED, Mahapatra TK, McManus PL, Lind MJ, Drew PJ, Cawkwell L.

Int J Surg. 2014;12(8):821-6. doi: 10.1016/j.ijsu.2014.06.009. Epub 2014 Jul 8.

4.

Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease.

Lin TT, Norris K, Heppel NH, Pratt G, Allan JM, Allsup DJ, Bailey J, Cawkwell L, Hills R, Grimstead JW, Jones RE, Britt-Compton B, Fegan C, Baird DM, Pepper C.

Br J Haematol. 2014 Oct;167(2):214-23. doi: 10.1111/bjh.13023. Epub 2014 Jul 3.

PMID:
24990087
5.

Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen.

Kashuba E, Eagle GL, Bailey J, Evans P, Welham KJ, Allsup D, Cawkwell L.

J Proteomics. 2013 Oct 8;91:478-85. doi: 10.1016/j.jprot.2013.08.002. Epub 2013 Aug 11.

PMID:
23938224
6.

The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers.

Kashuba E, Bailey J, Allsup D, Cawkwell L.

Biomarkers. 2013 Jun;18(4):279-96. doi: 10.3109/1354750X.2013.787544. Epub 2013 May 15. Review.

PMID:
23672534
7.

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697.

Agarwal V, Hodgkinson VC, Eagle GL, Scaife L, Lind MJ, Cawkwell L.

Int J Oncol. 2013 Mar;42(3):1088-92. doi: 10.3892/ijo.2013.1784. Epub 2013 Jan 22.

PMID:
23338544
8.

PTEN protein expression in malignant pleural mesothelioma.

Agarwal V, Campbell A, Beaumont KL, Cawkwell L, Lind MJ.

Tumour Biol. 2013 Apr;34(2):847-51. doi: 10.1007/s13277-012-0615-9. Epub 2012 Dec 15.

PMID:
23242608
9.

Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer.

Hodgkinson VC, Agarwal V, ELFadl D, Fox JN, McManus PL, Mahapatra TK, Kneeshaw PJ, Drew PJ, Lind MJ, Cawkwell L.

J Proteomics. 2012 May 17;75(9):2745-52. doi: 10.1016/j.jprot.2012.03.049. Epub 2012 Apr 3.

PMID:
22498883
10.

Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

Hodgkinson VC, ELFadl D, Agarwal V, Garimella V, Russell C, Long ED, Fox JN, McManus PL, Mahapatra TK, Kneeshaw PJ, Drew PJ, Lind MJ, Cawkwell L.

J Proteomics. 2012 Feb 2;75(4):1276-83. doi: 10.1016/j.jprot.2011.11.005. Epub 2011 Nov 15.

PMID:
22115752
11.

Differential proteomics in the search for biomarkers of radiotherapy resistance.

Scaife L, Hodgkinson VC, Drew PJ, Lind MJ, Cawkwell L.

Expert Rev Proteomics. 2011 Aug;8(4):535-52. doi: 10.1586/EPR.11.32. Review.

PMID:
21819306
12.

A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer.

Elfadl D, Hodgkinson VC, Long ED, Scaife L, Drew PJ, Lind MJ, Cawkwell L.

Breast. 2011 Aug;20(4):334-7. doi: 10.1016/j.breast.2011.02.017. Epub 2011 Mar 15.

13.

Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis.

Hodgkinson VC, ElFadl D, Drew PJ, Lind MJ, Cawkwell L.

J Proteomics. 2011 May 1;74(5):698-703. doi: 10.1016/j.jprot.2011.02.014. Epub 2011 Feb 19.

PMID:
21338725
14.

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

Agarwal V, Lind MJ, Cawkwell L.

Cancer Treat Rev. 2011 Nov;37(7):533-42. doi: 10.1016/j.ctrv.2010.11.004. Epub 2010 Dec 22. Review.

PMID:
21183281
15.

Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.

Murray A, Little SJ, Stanley P, Maraveyas A, Cawkwell L.

Oncol Rep. 2010 Oct;24(4):1049-58.

PMID:
20811688
16.

Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis.

Barkham N, Coates LC, Keen H, Hensor E, Fraser A, Redmond A, Cawkwell L, Emery P.

Ann Rheum Dis. 2010 Nov;69(11):1926-8. doi: 10.1136/ard.2009.121327. Epub 2010 May 28. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
20511615
17.

Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status.

Hodgkinson VC, Eagle GL, Drew PJ, Lind MJ, Cawkwell L.

Cancer Lett. 2010 Aug 1;294(1):13-24. doi: 10.1016/j.canlet.2010.01.036. Epub 2010 Feb 21. Review.

PMID:
20176436
18.

Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?

Smith L, Qutob O, Watson MB, Beavis AW, Potts D, Welham KJ, Garimella V, Lind MJ, Drew PJ, Cawkwell L.

Neoplasia. 2009 Nov;11(11):1194-207.

19.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

O'Kane SL, Eagle GL, Greenman J, Lind MJ, Cawkwell L.

Lung Cancer. 2010 Feb;67(2):160-5. doi: 10.1016/j.lungcan.2009.04.008. Epub 2009 May 17.

PMID:
19450893
20.

Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.

Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P.

Arthritis Rheum. 2009 Apr;60(4):946-54. doi: 10.1002/art.24408. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

21.

MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib.

Jarrett SJ, Sivera F, Cawkwell LS, Marzo-Ortega H, McGonagle D, Hensor E, Coates L, O'Connor PJ, Fraser A, Conaghan PG, Emery P.

Ann Rheum Dis. 2009 Sep;68(9):1466-9. doi: 10.1136/ard.2008.092213. Epub 2008 Oct 24. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
18952641
22.

Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.

Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H.

Rheumatology (Oxford). 2008 Jun;47(6):897-900. doi: 10.1093/rheumatology/ken094. Epub 2008 Apr 10.

PMID:
18403400
23.

The proteomic analysis of cisplatin resistance in breast cancer cells.

Smith L, Welham KJ, Watson MB, Drew PJ, Lind MJ, Cawkwell L.

Oncol Res. 2007;16(11):497-506.

PMID:
18306929
24.

Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience.

Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H.

Ann Rheum Dis. 2008 May;67(5):717-9. Epub 2007 Nov 30.

PMID:
18055476
25.

Genetic analysis of head and neck squamous cell carcinoma using comparative genomic hybridisation identifies specific aberrations associated with laryngeal origin.

Patmore HS, Ashman JN, Stafford ND, Berrieman HK, MacDonald A, Greenman J, Cawkwell L.

Cancer Lett. 2007 Dec 8;258(1):55-62.

PMID:
17920192
26.

The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy.

Smith L, Lind MJ, Drew PJ, Cawkwell L.

Eur J Cancer. 2007 Nov;43(16):2330-8. Epub 2007 Sep 20. Review.

PMID:
17888650
27.

Establishment of in-vitro models of chemotherapy resistance.

Watson MB, Lind MJ, Cawkwell L.

Anticancer Drugs. 2007 Aug;18(7):749-54. Review.

PMID:
17581296
28.

Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model.

Watson MB, Lind MJ, Smith L, Drew PJ, Cawkwell L.

Acta Oncol. 2007;46(5):651-8.

PMID:
17562441
29.

Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancer.

Garimella V, Long ED, O'Kane SL, Drew PJ, Cawkwell L.

Acta Oncol. 2007;46(2):204-7.

PMID:
17453370
30.
31.

The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays.

Smith L, Watson MB, O'Kane SL, Drew PJ, Lind MJ, Cawkwell L.

Mol Cancer Ther. 2006 Aug;5(8):2115-20.

32.

Expression of bcl-2 family members in malignant pleural mesothelioma.

O'Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ, Cawkwell L.

Acta Oncol. 2006;45(4):449-53.

PMID:
16760181
33.

Cancer proteomics and its application to discovery of therapy response markers in human cancer.

Smith L, Lind MJ, Welham KJ, Cawkwell L; Cancer Biology Proteomics Group.

Cancer. 2006 Jul 15;107(2):232-41. Review.

34.

Implication of the BRCA2 and putative "BRCA3" genes in Dukes' stage C, replication error-negative colon cancer.

Sivarajasingham NS, Cawkwell L, Baker RP, O'Kane SL, Smyth EF, Tilsed JV, Watson MB, Greenman J, Monson JR.

Ann Surg Oncol. 2006 Jun;13(6):881-6. Epub 2006 Apr 13.

PMID:
16614877
35.

Immunohistochemical detection of apoptotic markers in gastric cancer.

Smith L, Berrieman HK, O'Kane SL, Campbell A, Maraveyas A, Cawkwell L.

Oncol Res. 2006;15(9):441-4.

PMID:
16555550
36.

Mismatch repair, p53 and chromosomal aberrations in primary colorectal carcinomas.

Mehigan BJ, Ashman JN, Baker RP, Macdonald A, Greenman J, Monson JR, Cawkwell L.

Acta Oncol. 2006;45(1):61-6.

PMID:
16464797
37.

Hsp27 may allow prediction of the response to single-agent vinorelbine chemotherapy in non-small cell lung cancer.

Berrieman HK, Cawkwell L, O'Kane SL, Smith L, Lind MJ.

Oncol Rep. 2006 Jan;15(1):283-6.

PMID:
16328069
38.

Early oligoarthritis.

Marzo-Ortega H, Cawkwell L, Green MJ.

Rheum Dis Clin North Am. 2005 Nov;31(4):627-39. Review.

PMID:
16287588
39.

Unraveling the chromosomal aberrations of head and neck squamous cell carcinoma: a review.

Patmore HS, Cawkwell L, Stafford ND, Greenman J.

Ann Surg Oncol. 2005 Oct;12(10):831-42. Epub 2005 Aug 9. Review.

PMID:
16132373
40.

Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.

O'Kane SL, Cawkwell L, Campbell A, Lind MJ.

Eur J Cancer. 2005 Jul;41(11):1645-8.

PMID:
15964184
41.

Bcl-2 expression predicts radiotherapy failure in laryngeal cancer.

Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N.

Br J Cancer. 2005 Jun 20;92(12):2185-9.

42.

Assessment of dendritic cell number and radiosensitivity in laryngeal tumours.

Nix P, Stafford N, Cawkwell L, Greenman J.

Clin Otolaryngol. 2005 Apr;30(2):164-8.

PMID:
15839869
43.

Association between family history and mismatch repair in colorectal cancer.

Coggins RP, Cawkwell L, Bell SM, Crockford GP, Quirke P, Finan PJ, Bishop DT.

Gut. 2005 May;54(5):636-42.

44.

The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes.

Berrieman HK, Smith L, O'Kane SL, Campbell A, Lind MJ, Cawkwell L.

Cancer. 2005 Apr 1;103(7):1415-9.

45.

Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer.

Smyth EF, Sharma A, Sivarajasingham N, Hartley J, Monson JR, Cawkwell L.

Dis Colon Rectum. 2004 Dec;47(12):2086-91; discussion 2091-2.

PMID:
15657659
46.

Radioresistance in carcinoma of the breast.

Jameel JK, Rao VS, Cawkwell L, Drew PJ.

Breast. 2004 Dec;13(6):452-60. Review.

PMID:
15563851
47.

Defining the criteria for radioresistant laryngeal cancer.

Nix PA, Greenman J, Cawkwell L, Stafford ND.

Clin Otolaryngol Allied Sci. 2004 Dec;29(6):705-8.

PMID:
15533164
48.

Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients.

Titu LV, Loveday RL, Madden LA, Cawkwell L, Monson JR, Greenman J.

Oncol Rep. 2004 Oct;12(4):871-6.

PMID:
15375515
49.

Chromosomal alterations in breast cancer revealed by multicolour fluorescence in situ hybridization.

Watson MB, Bahia H, Ashman JN, Berrieman HK, Drew P, Lind MJ, Greenman J, Cawkwell L.

Int J Oncol. 2004 Aug;25(2):277-83.

PMID:
15254723
50.

Can a genetic signature for metastatic head and neck squamous cell carcinoma be characterised by comparative genomic hybridisation?

Patmore HS, Ashman JN, Cawkwell L, MacDonald A, Stafford ND, Greenman J.

Br J Cancer. 2004 May 17;90(10):1976-82. Erratum in: Br J Cancer. 2004 Aug 31;91(5):1001. James, NE Ashman [corrected to Ashman, JNE].

Supplemental Content

Loading ...
Support Center